{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:03:47Z","timestamp":1792652627048,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,5,30]],"date-time":"2014-05-30T00:00:00Z","timestamp":1401408000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s13277-014-2138-z","type":"journal-article","created":{"date-parts":[[2014,5,28]],"date-time":"2014-05-28T20:08:55Z","timestamp":1401307735000},"page":"8733-8742","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["MicroRNA-520a-5p displays a therapeutic effect upon chronic myelogenous leukemia cells by targeting STAT3 and enhances the anticarcinogenic role of capsaicin"],"prefix":"10.1007","volume":"35","author":[{"given":"Bur\u00e7in Tezcanl\u0131","family":"Kaymaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vildan Bozok","family":"\u00c7etinta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7a\u011fda\u015f","family":"Aktan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buket","family":"Kosova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,30]]},"reference":[{"issue":"3","key":"2138_CR1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z, O\u2019Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164\u201372.","journal-title":"N Engl J Med"},{"issue":"3","key":"2138_CR2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172\u201383.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"2138_CR3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","volume":"145","author":"HM Kantarjian","year":"2006","unstructured":"Kantarjian HM, Talpaz M, Giles F, O\u2019Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006;145(12):913\u201323.","journal-title":"Ann Intern Med"},{"issue":"5","key":"2138_CR4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1600-0609.2011.01689.x","volume":"87","author":"S Vaidya","year":"2011","unstructured":"Vaidya S, Ghosh K, Vundinti BR. Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review. Eur J Haematol. 2011;87(5):381\u201393.","journal-title":"Eur J Haematol"},{"issue":"5","key":"2138_CR5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561\u20136.","journal-title":"Nat Med"},{"issue":"5531","key":"2138_CR6","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531):876\u201380.","journal-title":"Science"},{"issue":"5","key":"2138_CR7","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118(5):1208\u201315.","journal-title":"Blood"},{"issue":"1","key":"2138_CR8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11899-012-0152-z","volume":"8","author":"K Machova Polakova","year":"2013","unstructured":"Machova Polakova K, Koblihova J, Stopka T. Role of epigenetics in chronic myeloid leukemia. Curr Hematol Malig Rep. 2013;8(1):28\u201336.","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"2138_CR9","first-page":"131","volume":"10","author":"J Liu","year":"2013","unstructured":"Liu J, Wu CP, Lu BF, Jiang JT. Mechanism of T cell regulation by microRNAs. Cancer Biol Med. 2013;10(3):131\u20137.","journal-title":"Cancer Biol Med"},{"key":"2138_CR10","doi-asserted-by":"crossref","unstructured":"Ho CS, Yap SH, Phuah NH, In LL, Hasima N. MicroRNAs associated with tumour migration, invasion and angiogenic properties in A549 and SK-Lu1 human lung adenocarcinoma cells. Lung Cancer. 2013.","DOI":"10.1016\/j.lungcan.2013.11.024"},{"issue":"3","key":"2138_CR11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4161\/rna.8.3.14333","volume":"8","author":"TB Hansen","year":"2011","unstructured":"Hansen TB, Kjems J, Bramsen JB. Enhancing miRNA annotation confidence in miRBase by continuous cross dataset analysis. RNA Biol. 2011;8(3):378\u201383.","journal-title":"RNA Biol"},{"issue":"21","key":"2138_CR12","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.2174\/138161208785294627","volume":"14","author":"E Barbarotto","year":"2008","unstructured":"Barbarotto E, Calin GA. Potential therapeutic applications of miRNA-based technology in hematological malignancies. Curr Pharm Des. 2008;14(21):2040\u201350.","journal-title":"Curr Pharm Des"},{"issue":"5","key":"2138_CR13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s13402-012-0095-3","volume":"35","author":"S Babashah","year":"2012","unstructured":"Babashah S, Sadeghizadeh M, Tavirani MR, Farivar S, Soleimani M. Aberrant microRNA expression and its implications in the pathogenesis of leukemias. Cell Oncol (Dordr). 2012;35(5):317\u201334.","journal-title":"Cell Oncol (Dordr)"},{"issue":"8","key":"2138_CR14","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3324\/haematol.2009.020636","volume":"95","author":"S Flamant","year":"2010","unstructured":"Flamant S, Ritchie W, Guilhot J, Holst J, Bonnet ML, Chomel JC, et al. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica. 2010;95(8):1325\u201333.","journal-title":"Haematologica"},{"issue":"4","key":"2138_CR15","doi-asserted-by":"crossref","first-page":"e35501","DOI":"10.1371\/journal.pone.0035501","volume":"7","author":"OH Rokah","year":"2012","unstructured":"Rokah OH, Granot G, Ovcharenko A, Modai S, Pasmanik-Chor M, Toren A, et al. Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS One. 2012;7(4):e35501.","journal-title":"PLoS One"},{"issue":"3","key":"2138_CR16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5505\/kjms.2013.39200","volume":"3","author":"BT Kaymaz","year":"2013","unstructured":"Kaymaz BT, Cetintas VB, Kosova B. Determination of the gene expression profiles of JAK\/STAT cascade components for the potential role of capsaicin induced apoptosis of acute T-cell lymphoblastic leukemia cells. Kafkas J Med Sci. 2013;3(3):129\u201335.","journal-title":"Kafkas J Med Sci"},{"issue":"3A","key":"2138_CR17","first-page":"1965","volume":"26","author":"MF Tsou","year":"2006","unstructured":"Tsou MF, Lu HF, Chen SC, Wu LT, Chen YS, Kuo HM, et al. Involvement of Bax, Bcl-2, Ca2+ and caspase-3 in capsaicin-induced apoptosis of human leukemia HL-60 cells. Anticancer Res. 2006;26(3A):1965\u201371.","journal-title":"Anticancer Res"},{"issue":"3","key":"2138_CR18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0145-2126(02)00164-9","volume":"27","author":"J Zhang","year":"2003","unstructured":"Zhang J, Nagasaki M, Tanaka Y, Morikawa S. Capsaicin inhibits growth of adult T-cell leukemia cells. Leuk Res. 2003;27(3):275\u201383.","journal-title":"Leuk Res"},{"issue":"1\u20132","key":"2138_CR19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0027-5107(97)00305-9","volume":"402","author":"YJ Surh","year":"1998","unstructured":"Surh YJ, Lee E, Lee JM. Chemoprotective properties of some pungent ingredients present in red pepper and ginger. Mutat Res. 1998;402(1\u20132):259\u201367.","journal-title":"Mutat Res"},{"issue":"6","key":"2138_CR20","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1073\/pnas.92.6.1831","volume":"92","author":"DJ Morre","year":"1995","unstructured":"Morre DJ, Chueh PJ, Morre DM. Capsaicin inhibits preferentially the NADH oxidase and growth of transformed cells in culture. Proc Natl Acad Sci U S A. 1995;92(6):1831\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"2138_CR21","doi-asserted-by":"crossref","first-page":"L165","DOI":"10.1016\/S0024-3205(99)00046-6","volume":"64","author":"K Takahata","year":"1999","unstructured":"Takahata K, Chen X, Monobe K, Tada M. Growth inhibition of capsaicin on HeLa cells is not mediated by intracellular calcium mobilization. Life Sci. 1999;64(13):L165\u201371.","journal-title":"Life Sci"},{"issue":"2","key":"2138_CR22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/sj.cdd.4400465","volume":"6","author":"A Macho","year":"1999","unstructured":"Macho A, Calzado MA, Munoz-Blanco J, Gomez-Diaz C, Gajate C, Mollinedo F, et al. Selective induction of apoptosis by capsaicin in transformed cells: the role of reactive oxygen species and calcium. Cell Death Differ. 1999;6(2):155\u201365.","journal-title":"Cell Death Differ"},{"issue":"6","key":"2138_CR23","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1158\/1078-0432.CCR-1142-03","volume":"10","author":"K Ito","year":"2004","unstructured":"Ito K, Nakazato T, Murakami A, Yamato K, Miyakawa Y, Yamada T, et al. Induction of apoptosis in human myeloid leukemic cells by 1\u2032-acetoxychavicol acetate through a mitochondrial- and Fas-mediated dual mechanism. Clin Cancer Res. 2004;10(6):2120\u201330.","journal-title":"Clin Cancer Res"},{"key":"2138_CR24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1744-8069-7-17","volume":"7","author":"R Kusuda","year":"2011","unstructured":"Kusuda R, Cadetti F, Ravanelli MI, Sousa TA, Zanon S, De Lucca FL, et al. Differential expression of microRNAs in mouse pain models. Mol Pain. 2011;7:17.","journal-title":"Mol Pain"},{"issue":"2","key":"2138_CR25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00277-012-1575-2","volume":"92","author":"BT Kaymaz","year":"2013","unstructured":"Kaymaz BT, Selvi N, Gunduz C, Aktan C, Dalmizrak A, Saydam G, et al. Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K-562 with unmodified or chemically modified siRNAs and induction of apoptosis. Ann Hematol. 2013;92(2):151\u201362.","journal-title":"Ann Hematol"},{"issue":"2","key":"2138_CR26","first-page":"55","volume":"1","author":"M Bar-Natan","year":"2012","unstructured":"Bar-Natan M, Nelson EA, Xiang M, Frank DA. STAT signaling in the pathogenesis and treatment of myeloid malignancies. JAKSTAT. 2012;1(2):55\u201364.","journal-title":"JAKSTAT"},{"issue":"4","key":"2138_CR27","first-page":"292","volume":"1","author":"SR Walker","year":"2012","unstructured":"Walker SR, Frank DA. Screening approaches to generating STAT inhibitors: allowing the hits to identify the targets. JAKSTAT. 2012;1(4):292\u20139.","journal-title":"JAKSTAT"},{"issue":"6","key":"2138_CR28","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.3892\/ijo.2012.1647","volume":"41","author":"A Allegra","year":"2012","unstructured":"Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, et al. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol. 2012;41(6):1897\u2013912.","journal-title":"Int J Oncol"},{"issue":"10","key":"2138_CR29","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","volume":"20","author":"E Jabbour","year":"2006","unstructured":"Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O\u2019Brien S, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006;20(10):1767\u201373.","journal-title":"Leukemia"},{"issue":"7","key":"2138_CR30","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1080\/13547500802646572","volume":"13","author":"M Osaki","year":"2008","unstructured":"Osaki M, Takeshita F, Ochiya T. MicroRNAs as biomarkers and therapeutic drugs in human cancer. Biomarkers. 2008;13(7):658\u201370.","journal-title":"Biomarkers"},{"key":"2138_CR31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1476-4598-8-69","volume":"8","author":"E San Jose-Eneriz","year":"2009","unstructured":"San Jose-Eneriz E, Roman-Gomez J, Jimenez-Velasco A, Garate L, Martin V, Cordeu L, et al. MicroRNA expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. Mol Cancer. 2009;8:69.","journal-title":"Mol Cancer"},{"issue":"1","key":"2138_CR32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2011.04.006","volume":"131","author":"E Sotillo","year":"2011","unstructured":"Sotillo E, Thomas-Tikhonenko A. Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol Ther. 2011;131(1):18\u201332.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"2138_CR33","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.leukres.2011.08.023","volume":"36","author":"V Scholl","year":"2012","unstructured":"Scholl V, Hassan R, Zalcberg IR. miRNA-451: a putative predictor marker of imatinib therapy response in chronic myeloid leukemia. Leuk Res. 2012;36(1):119\u201321.","journal-title":"Leuk Res"},{"issue":"1","key":"2138_CR34","first-page":"183","volume":"19","author":"V Bozok Cetintas","year":"2014","unstructured":"Bozok Cetintas V, Tezcanli Kaymaz B, Aktug H, Oltulu F, Taskiran D. Capsaicin induced apoptosis and gene expression dysregulation of human acute lymphoblastic leukemia CCRF-CEM cells. J BUON. 2014;19(1):183\u201390.","journal-title":"J BUON"},{"key":"2138_CR35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1755-8794-4-79","volume":"4","author":"CH Kim","year":"2011","unstructured":"Kim CH, Kim HK, Rettig RL, Kim J, Lee ET, Aprelikova O, et al. miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics. 2011;4:79.","journal-title":"BMC Med Genomics"},{"issue":"4","key":"2138_CR36","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/sj.bjc.6605787","volume":"103","author":"I Auwera Van der","year":"2010","unstructured":"Van der Auwera I, Limame R, van Dam P, Vermeulen PB, Dirix LY, Van Laere SJ. Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. Br J Cancer. 2010;103(4):532\u201341.","journal-title":"Br J Cancer"},{"issue":"3","key":"2138_CR37","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/onc.2012.51","volume":"32","author":"S Catuogno","year":"2013","unstructured":"Catuogno S, Cerchia L, Romano G, Pognonec P, Condorelli G, de Franciscis V. miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene. 2013;32(3):341\u201351.","journal-title":"Oncogene"},{"issue":"5332","key":"2138_CR38","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.277.5332.1630","volume":"277","author":"JE Darnell Jr","year":"1997","unstructured":"Darnell Jr JE. STATs and gene regulation. Science. 1997;277(5332):1630\u20135.","journal-title":"Science"},{"issue":"2","key":"2138_CR39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrc1275","volume":"4","author":"H Yu","year":"2004","unstructured":"Yu H, Jove R. The STATs of cancer\u2013new molecular targets come of age. Nat Rev Cancer. 2004;4(2):97\u2013105.","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"2138_CR40","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.2174\/092986711795843218","volume":"18","author":"A Lavecchia","year":"2011","unstructured":"Lavecchia A, Di Giovanni C, Novellino E. STAT-3 inhibitors: state of the art and new horizons for cancer treatment. Curr Med Chem. 2011;18(16):2359\u201375.","journal-title":"Curr Med Chem"},{"issue":"6","key":"2138_CR41","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.nutres.2011.05.007","volume":"31","author":"SE Choi","year":"2011","unstructured":"Choi SE, Kim TH, Yi SA, Hwang YC, Hwang WS, Choe SJ, et al. Capsaicin attenuates palmitate-induced expression of macrophage inflammatory protein 1 and interleukin 8 by increasing palmitate oxidation and reducing c-Jun activation in THP-1 (human acute monocytic leukemia cell) cells. Nutr Res. 2011;31(6):468\u201378.","journal-title":"Nutr Res"},{"issue":"2","key":"2138_CR42","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1080\/01635581.2011.523497","volume":"63","author":"D Dou","year":"2011","unstructured":"Dou D, Ahmad A, Yang H, Sarkar FH. Tumor cell growth inhibition is correlated with levels of capsaicin present in hot peppers. Nutr Cancer. 2011;63(2):272\u201381.","journal-title":"Nutr Cancer"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-014-2138-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-014-2138-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-014-2138-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T23:21:59Z","timestamp":1565479319000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-014-2138-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,30]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["2138"],"URL":"https:\/\/doi.org\/10.1007\/s13277-014-2138-z","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,30]]}}}